Morning Brief — Friday, July 25, 2026

Market Overview

Markets are navigating a challenging backdrop: Brent crude topped $100/barrel amid escalating U.S.-Iran tensions in the Middle East, driving Treasury yields to year-highs and triggering a broad tech selloff Thursday that hit the Nasdaq particularly hard. Today’s session opens with a bifurcated tape — energy and defense names catching bids on the geopolitical premium while the Magnificent Seven continue to bleed, with TSLA and GOOGL leading the “MAGS” ETF toward its worst single-day loss of 2026. Earnings season is in full swing and largely beating estimates, providing a partial floor, but rising oil prices + higher-for-longer rate fears are the dominant macro narrative squeezing growth multiples.

Claude’s Call

DOWN — The combination of $100+ crude stoking inflation fears, surging Treasury yields, and a Magnificent Seven breakdown creates a negative feedback loop that will keep the S&P 500 under pressure today; even solid earnings beats (SLB, THC, BAH) are being celebrated in pockets but won’t overcome macro headwinds, and with GOOGL near 6-month lows and TSLA breaking critical support at $319, index-level selling pressure should persist into the close.

Top Movers

NVCR (+28.4%) — $19.99 → $24.08 (+20.5% upside from current) Thesis: This is a legitimate fundamental catalyst, not a sympathy play — Novocure reported its “strongest commercial quarter to date” with double-digit Optune revenue growth, raised its full-year 2026 outlook, and is sitting on an imminent FDA premarket approval for its brain therapy candidate. The stock broke out of a 6-month base (prior low $10.03), hit a new 52-week high at $20.55, and the RSI at 68.4 suggests momentum without being fully overbought yet. Management tone is clearly confident — they’re leading with raised guidance and FDA catalysts, not dodging questions. This move has real legs if the PMA lands. Levels: Exit target at fib 1.272 extension of $24.08. Support at 23.6% fib retracement ($18.47) — that’s your natural pullback zone if the FDA news gets delayed.

THRM (+26.5%) — $45.61 → $51.24 (+12.4% upside) Thesis: Gentherm delivered record quarterly product revenue AND raised full-year guidance AND announced a new multi-year share repurchase program — that’s a triple catalyst in one print, which is why this moved 26%. The analyst community is calling it 39% below fair value post-print. Technically, THRM broke out above its 6-month range (prior high was $46.10, which it’s testing now), and the RSI is only at 30.22 — that’s unusually low for a name ripping 26%, suggesting this was deeply oversold before the print and the move is a reset, not a blow-off. Automotive demand recovery + medical sector diversification = durable thesis. Levels: Exit at fib 1.272 extension of $51.24. Strong support at 23.6% retracement ($41.65) — a pullback to $41-42 would be a gift. The SMA-50 at $35.31 is a distant backstop.

THC (+20.6%) — $240.00 → $267.49 (+11.5% upside) Thesis: Tenet Healthcare crushed Q2 — EPS beat by +50% and revenue beat by +4.4% — and “significantly increased” its full-year outlook. The +50% EPS beat isn’t a one-liner; it reflects better-than-feared ambulatory care volumes and higher revenue per admission offsetting lower patient days, exactly the concern analysts had pre-print. This stock was a consensus short given hospital sector fears (Medicaid cuts, volume headwinds), so the squeeze here is real and the guidance raise is the key catalyst for continued upside. RSI at 24.95 coming into this print — the stock was massively oversold. Technically, it’s pressing near the 6-month high of $244.80 — a clean breakout above that level confirms the next leg. Levels: Exit at fib 1.272 extension of $267.49. Immediate support at 23.6% fib ($225.11). The SMA-50 at $186.09 is your worst-case floor — would only see that on a macro healthcare policy shock.

MEDP (+14.7%) — $605.82 → $663.59 (+9.5% upside) Thesis: Medpace reversed its Q1 malaise decisively — revenue beat by ~$17.6M (+2.6%), GAAP EPS of $4.25 beat the $3.99 consensus, and critically, bookings came in well above expectations, which is the leading indicator for a CRO business. The “bookings beat” story is what gives this legs — it signals pipeline health, not just a quarterly accounting beat. Context matters: this stock was under pressure all year on fears that biotech funding tightening would hurt CRO demand. That thesis appears wrong. RSI at 20.28 — this was the most oversold stock on the list before today’s catalyst. This is a textbook “beaten-down quality name with a real catalyst” setup. Levels: Exit at fib 1.272 extension of $663.59. Support cluster at 23.6% fib ($555.69) / SMA-50 ($488.10). Don’t chase if it fades below $580.

THC and MEDP are the two cleanest “buy the breakout with conviction” setups today.

KALU (+9.9%) — $180.60 → $219.86 (+21.7% upside) Thesis: Kaiser Aluminum beat Q2 EPS by a massive +138% and revenue by +6.9% — the earnings surprise here is enormous. Management cited “broad-based demand improvement across most end markets, record conversion revenue, and metal-related tailwinds.” The Trump aluminum/defense supply chain executive orders from July 20th are a secondary tailwind — this is one of those rare cases where the policy tailwind and fundamental beat are happening simultaneously. Technically, KALU is just off its 20-day high of $195.63 and sitting near the SMA-50 ($176.21) — it’s not overextended. The 6-month high of $195.63 is the first resistance test. Levels: Exit at fib 1.272 extension of $219.86. Support at 23.6% fib ($174.60) which coincides tightly with the SMA-50 ($176.21) — a very clean support cluster.

BAH (+8.2%) — $71.26 → $101.45 (+42.4% upside to fib 1.272) Thesis: Booz Allen beat EPS by +21.5% but missed on revenue (-4.2% YoY to $2.8B) — this is a nuanced beat. Management maintained its full-year outlook and highlighted “accelerating demand” across key areas. The market is rewarding margin execution over top-line growth, which makes sense for a defense consulting name in a DOGE-adjacent environment where cost efficiency is scrutinized. The caveat: revenue miss matters for a services business, and the stock is well off its 6-month high of $92.52. This isn’t a clean breakout — it’s a relief rally from deeply oversold levels (price was near its 6-month low of $59.71 recently). RSI at 62.9 is the most “normal” on this list — not oversold at the entry. Levels: Immediate resistance at 6-month high $92.52 (realistic near-term target), then fib 1.272 at $101.45. Support at the SMA-50 ($70.30) which is basically current price — if it breaks below $70, this fades fast.

DLR (+6.5%) — $191.02 → $214.29 (+12.2% upside) Thesis: Digital Realty raised its full-year FFO outlook after record leasing, with AI/cloud demand driving a “sharply larger backlog” and unusually strong renewal pricing. The planned acquisition of Blackstone’s stakes in three fully-leased hyperscale data centers adds incremental scale. In an environment where the Magnificent Seven are selling off partly on AI capex fears, DLR is the “picks and shovels” play that’s actually benefiting from that capex — hyperscalers are spending on DLR’s infrastructure. One analyst note today flagged ~31.8% undervaluation on DCF basis. The stock is approaching its 6-month high of $202.56 — that’s the first real resistance test. Levels: Exit at 6-month high $202.56 near-term, then fib 1.272 at $214.29. Support at 23.6% fib ($192.38) — essentially right here, making this a tight risk/reward entry.

WKC (+6.2%) — $38.52 → $45.29 (+17.6% upside) Thesis: World Kinect crushed Q2 with a +72% EPS beat and revenue beat of +29.7%, delivering “highest-ever quarterly adjusted EPS and gross profits,” and raised full-year guidance. The driver? Middle East oil volatility is a direct profit tailwind for an energy management/fuel distribution company — geopolitical risk is literally their business model right now. With Brent at $100+, this tailwind isn’t going away. This is a contrarian “oil spike winner” in a day when oil is hurting most names. At 6-month highs and RSI at 50, it’s not overextended. Clean breakout setup. Levels: Exit at fib 1.272 extension of $45.29. Support at 23.6% fib ($36.08). SMA-50 at $31.95 is the hard floor.

SLB (+7.4%) — $50.70 → $61.73 (+21.8% upside) Thesis: SLB beat Q2 EPS by +7.8% and revenue by +2.95%, with offshore activity and data center demand (yes — SLB is diversifying into AI infrastructure services) offsetting Middle East disruption. At $100 Brent, the macro tailwind for oilfield services is building. The stock broke above its 20-day high today. One risk: the 6-month high is $58.01 and current price at $50.70 still has room, but the fib extension targets suggest meaningful upside to $61-66. This is the cleanest energy sector play with a real fundamental beat behind it. Levels: Exit near 6-month high $58.01 (first target), then fib 1.272 at $61.73. Support at 61.8% fib ($49.55) — just below current price, making this a tight stop.

FCNCA (+6.5%) — $2,212.77 → $2,354.99 (+6.4% upside) Thesis: First Citizens BancShares crushed Q2 — EPS beat by +41.1% and revenue beat by +3.7% (+10.1% YoY to $2.43B). Strong loan and deposit growth in a competitive deposit environment is the key story. At $2,200+, this is a Berkshire-priced regional bank that doesn’t get enough coverage. The valuation remains compelling for a bank delivering 10%+ revenue growth with blowout earnings. Technically it’s at a 6-month high — momentum is clean. The risk: rising rates are a two-sided sword for banks, and the deposit competition language on the call warrants watching. Levels: Exit at fib 1.272 extension of $2,354.99. Support at 23.6% fib ($2,119.03). Stop below $2,044 (20-day low).

Headlines to Watch

“Brent Crude Tops $100 as Iran-U.S. Tensions Intensify” — The single most important macro driver today; every inflation-sensitive sector (growth tech, consumer discretionary) faces headwinds while energy, defense, and commodity stocks get a direct bid — rotate accordingly.
“TSLA, GOOGL Lead Magnificent Seven Rout — MAGS ETF Toward Biggest Single-Day Loss This Year” — Alphabet’s negative free cash flow warning combined with Tesla’s technical breakdown below key support ($319 area) signals the AI capex story is being repriced; watch whether GOOGL holds $319 (61.8% fib support) or breaks into free-fall.
“Morgan Stanley Sees 141% Upside for Hut 8, $263 Price Target — AI Data Center Pivot” — HUT’s 28% weekly surge is being driven by a legitimate thesis: grid-connected power assets are scarce, and Morgan Stanley sees bitcoin miners as AI infrastructure plays; the $9.8B AI lease with Beacon Point (per Rosenblatt) is the specific catalyst.
“Alphabet Reveals Scary Risk — Negative Free Cash Flow Warning” — This has broader implications: if the largest AI spender is bleeding cash at the index level, it validates the capex concerns that hit GOOGL/META/MSFT; watch for contagion into cloud/AI infrastructure names that haven’t yet reported.
“Trump Signs Orders on Aluminum and Defense Supply Chains — AA, KALU, CENX, MP in Focus” — The policy tailwind for domestic metals producers is real and complementary to KALU’s fundamental beat; this could extend the aluminum trade into next week, especially with trade war uncertainty ongoing.
“Digital Realty Raises FFO Outlook After Record AI Leasing — Acquires Blackstone Hyperscale Stakes” — DLR is the clearest “picks and shovels” beneficiary when hyperscalers are spending heavily on data center capacity; the Blackstone acquisition adds quality, fully-leased assets to the portfolio — this is durable, not cyclical.
“SS&C Technologies Reports Record Q2 Revenue (+10.3% YoY) but Q3 Guidance Misses by 0.6%” — The near-term guidance miss is what’s holding SSNC back from a bigger move; the AI advancements narrative is real but investors are rightly focused on the modest guide — watch this one carefully before sizing up.

Claude’s Top Picks

THC (+20.6% today, +23.1% week) — $240.00 → $267.49 (+11.5% upside) Valuation: No comps data provided, but a +50% EPS beat on a healthcare name that was consensus-shorted suggests significant re-rating room remains as the short squeeze unwinds. Upside: Guidance raise was “significant” — the forward estimate revision cycle is just beginning, and analyst price target upgrades will follow over the next 1-2 weeks creating a second leg. Risk: If Congress resurfaces Medicaid cut legislation or hospital sector headlines turn negative, this gives back gains quickly — healthcare policy risk is always binary.

MEDP (+14.7% today, +12.6% week) — $605.82 → $663.59 (+9.5% upside) Valuation: No direct comps in the data, but CRO peers (IQVIA, PPD) trade at meaningful premiums to growth — MEDP at these levels post a bookings beat looks like fair-to-cheap value for a 17%+ revenue grower. Upside: The bookings beat is a leading indicator — new business won today becomes revenue in 6-12 months, meaning the growth runway is firming just as the stock was being abandoned; RSI at 20 coming in means the mean-reversion trade still has room. Risk: If biotech funding tightens again (rate spike scenario is live given $100 oil) or a key customer delays trials, bookings can be lumpy and the thesis unravels quickly.

KALU (+9.9% today, +12.6% week) — $180.60 → $219.86 (+21.7% upside) Valuation: No direct comps provided, but a +138% EPS beat on a cyclical industrial at current prices suggests the market was pricing in a much worse scenario — significant re-rating potential ahead. Upside: The policy tailwind (Trump aluminum orders) + fundamental beat + $100 oil supporting industrial demand is a three-layer thesis; the SMA-50 at $176.21 just below current price provides a technical floor that makes the risk/reward attractive. Risk: Aluminum is cyclical — if macro deteriorates sharply (recession fears from $100 oil + rate spike), industrial demand collapses faster than policy tailwinds can offset; tariff relief could also be reversed.

DLR (+6.5% today, +9.9% week) — $191.02 → $214.29 (+12.2% upside) Valuation: No comps provided, but Data Center REITs trade at premium FFO multiples — a raised FFO outlook with record leasing backlogs and AI demand acceleration justifies a premium; the DCF analysis flagged 31.8% undervaluation today. Upside: The Blackstone acquisition of fully-leased hyperscale assets is immediately accretive; in a market where AI capex fears are hitting hyperscalers, DLR is the landlord collecting rent from that capex — it’s the safer expression of the AI theme. Risk: Rising Treasury yields (the current macro risk) are the structural enemy of REITs — if the 10-year keeps climbing on $100 oil inflation fears, DLR’s premium valuation compresses even if fundamentals remain strong.

WKC (+6.2% today, +5.5% week) — $38.52 → $45.29 (+17.6% upside) Valuation: Trading at low single-digit multiples for an energy distribution business — at $100 Brent with record gross profits and raised guidance, this is genuinely cheap for the earnings power it’s demonstrating. Upside: Middle East volatility is directly accretive to WKC’s business model (fuel price spread management, marine/aviation fuel distribution) — as long as the Iran conflict simmers, this tailwind extends; the +72% EPS beat is not a fluke, it’s structural to the current environment. Risk: A sudden geopolitical de-escalation or oil price reversal would remove the primary earnings driver; this is a momentum trade on geopolitical tension, not a fundamental compounder — size accordingly.

Avoid

SAFT (+41.4% today) — Trading at a fresh 6-month and all-time high at $103.09 with a 41% single-day gain on no earnings catalyst visible in the news (most recent relevant news is from May 2026) — this looks like a technical squeeze or speculative spike with no identifiable fundamental driver today. Already past the 6-month high with volume below average (0.86x) — the move lacks conviction and is a classic “mystery mover” trap. The first meaningful support isn’t until $89.76 (38.2% fib), representing 13% downside from current levels with no clear reason to hold.

MGRT (+12.8% today, +29.9% week) — Mega Fortune Company is a Hong Kong-based IoT solutions provider that Jim Cramer literally told people to take profits on in April when it was at $135 (it’s now at $100, still down from those levels). The RSI at 21.25 and the week’s 30% move on a stock with no recent material news is a red flag. The 6-month high was $142.20 — this is a violent, low-liquidity small-cap with limited US-listed disclosure and no recent earnings catalyst. The fib structure is extremely wide (6mo low of $4.81 to high of $142.20) indicating massive historical volatility. Stay away.

HUT (+7.1% today, +28% week) — Hut 8 has run 28% in a week on the Morgan Stanley AI data center pivot thesis and a $9.8B AI lease announcement. At $117.67, it’s already past the 20-day high of $123.02 from above and pressing against the 6-month high of $133.02. The Rosenblatt 2028 revenue forecast of $1.8B is the key risk: delivery and construction risk on multi-year AI infrastructure leases is real (see the Mark Cuban/O’Leary Utah project headline today). The RSI at 13.11 is curiously low for a stock up 28% — data anomaly aside, chasing a bitcoin miner/AI pivot story at 6-month highs after a 28% week in a rising rate environment is not where you want to be adding risk.

WSB Sentiment Check

TSLA — WSB says: MIXED (55% bullish) Claude says: DISAGREE with the bulls — TSLA is breaking below its 6-month low support at $319.69 (current price $321.10 is right on that knife’s edge), the SMA-50 is miles above at $402.72, and there is no near-term fundamental catalyst to reverse a stock that’s down 28% from its 6-month high of $445.27; the 55% bullish reading at WSB is exactly the kind of “hopium hold” that has trapped retail longs all year.

INTC — WSB says: BULLISH (80% bullish) Claude says: PARTIALLY AGREE — Intel is at an inflection point: at $100.85 it’s sitting right on the 38.2% fib support ($102.84), which is actually a reasonable technical entry near a key level; the 80% WSB bullish sentiment is high but the fundamental story (post-merger/restructuring recovery, blowout Q2 expected) has merit; the risk is that the stock has failed at the SMA-50 ($115.44) multiple times in the 6-month range — bulls need a clean break above $115 to confirm the thesis, not just hope.

SPCX — WSB says: MIXED (55% bullish) Claude says: DISAGREE — SPCX is at its 6-month LOW of $115.21 (the 6-month high was $211.39 — that’s a 45% drawdown), there is no SMA-50 data suggesting this is a newly listed or restructured vehicle, and ALL the fib retracement levels are ABOVE current price (the 61.8% fib “support” is at $151.95, which is above current price because it’s calculated from the top down). This is a falling knife with no floor visible in the technical data. Mixed WSB sentiment on a name in freefall is a trap — the 55% bulls are catching swords.

MU — WSB says: MIXED (55% bullish) Claude says: PARTIALLY AGREE — Micron at $966 is sitting right near the 23.6% fib support ($1,002.95) having pulled back hard from its $1,213 6-month high; the memory cycle is real and AI DRAM demand is a legitimate structural driver; however, the stock needs to hold $872 (38.2% fib) on any macro deterioration or it gets ugly fast; the mixed sentiment is actually appropriate here — this is a “wait for the dust to settle” name, not a conviction buy at current levels in a rising-rate environment.

GOOG — WSB says: BEARISH (30% bullish) Claude says: AGREE — Alphabet is testing its 61.8% fib support at $321.04 right now (current price $319.68) and the negative free cash flow headline today is a genuine sentiment changer; the SMA-50 at $362.28 is ~13% above, making any near-term recovery an uphill battle; the bearish WSB read is warranted — the AI capex overspend narrative is gaining traction and GOOG is the poster child for it this week. If $319 breaks cleanly, the next meaningful support doesn’t appear until the 6-month low near $272.98 — that’s real downside.

Earnings Scorecard

SAP — BEAT | Stock: +6.1% | Reported: Yesterday Strong cloud business resilience reassured investors worried about AI disruption risk — the reaction is justified. SAP is a quality compounder and the 6% move on cloud beat is a normal, healthy re-rating. Not a buy-the-dip, not a sell-the-rip — hold or add on pullback.

NOW — BEAT | Stock: +5.0% | Reported: Yesterday ServiceNow delivered but UBS flagged “mixed demand signals” even amid the beat — the muted 5% reaction suggests the market is appropriately cautious. Analyst targets being hiked but the stock is in a crowded long. Hold — don’t chase the gap.

TMUS — BEAT | Stock: +4.6% | Reported: Yesterday EPS of $9.56 with higher FCF and buybacks is a compelling telecoms print — the +4.6% reaction actually understates the quality of the beat per the analyst coverage (“could be 33% undervalued”). Reaction is insufficient — this is a buy-the-dip candidate on any pullback.

UNP — BEAT | Stock: +4.0% | Reported: Yesterday Record revenue from Union Pacific in a tough macro environment is impressive — the +4% reaction is justified for a defensive rail name. Not a momentum trade, but hold for dividend income and macro hedge.

VZ — BEAT | Stock: +3.2% | Reported: Yesterday Raised guidance for the second straight quarter with CEO calling it the carrier’s “strongest operating position in years” — yet only +3.2%? Reaction is insufficient. Telecoms are boring but this is a buy-the-dip on yield-seeking in a high-rate environment.

HCA — BEAT | Stock: +2.1% | Reported: Yesterday HCA set up the positive read-through for THC today — the muted +2% reaction on HCA suggests the hospital sector was deeply skeptical; in hindsight the sector was oversold. Buy-the-dip on any pullback — the sector re-rating is underway, confirmed by THC’s +50% EPS beat today.

CMCSA — REPORTED | Stock: -1.3% | Reported: Yesterday Peacock turned profitable AND NBCUniversal spin-off announced — that’s genuinely newsworthy. The -1.3% reaction likely reflects spin-off complexity/execution risk discounting. Reaction may be overdone to the downside — Peacock profitability is a major milestone. Speculative buy-the-dip for patient holders.

NEM — BEAT | Stock: -1.2% | Reported: Yesterday Beat on EPS but missed on volumes — the sell-off is justified because gold miners are ultimately valued on production, not just margins. Lower volumes signal operational challenges. Avoid near-term — don’t buy this dip.

TXN — BEAT | Stock: -1.2% | Reported: Yesterday Strong Q2 and in-line Q3 outlook “largely meets elevated expectations” per Morgan Stanley — the flat-to-down reaction is classic “buy the rumor, sell the news” on a stock that had already run into earnings. Reaction justified. Hold existing positions but don’t add here.

DHR — BEAT | Stock: -1.1% | Reported: Yesterday Mixed results with strengthened 2027+ outlook — market is penalizing near-term execution while rewarding forward guidance, hence the muted negative reaction. RBC is constructive but the “don’t quit on Danaher” headline says it all — this is a hold with a buy-the-dip trigger on a meaningful flush toward prior support.

PM — BEAT | Stock: +1.0% | Reported: Yesterday Nicotine pouch rebound is real — Philip Morris is one of the few defensive names with genuine earnings growth in a rising-rate world. The +1% reaction is understated for a quality compounder with pricing power. This is a buy for defensive rotation as the Magnificent Seven unravels.

RTX — BEAT | Stock: +0.6% | Reported: Yesterday RTX raised its outlook and jumped 8% on the print (per headline) but is now +0.6% net — defense names are catching two Iran-war headwinds that are tempering the enthusiasm post-beat. The reaction looks slightly muted given the raise. Buy-the-dip on defense broadly — if Iran tensions escalate, RTX is a direct beneficiary.

CME — BEAT | Stock: -0.7% | Reported: Yesterday Record revenue but -0.7% reaction — market volatility drives CME volumes and thus earnings, so this beat was partly anticipated